Tetramisole hydrochloride:Exports & Compliance White Paper 2026

I. Executive Summary

Tetramisole hydrochloride (CAS 5086-74-8) is the hydrochloride salt of tetramisole, the racemic form of the imidazothiazole anthelmintic whose levorotatory enantiomer is levamisole. It is supplied as a white to off-white crystalline solid, freely soluble in water and methanol, with a molecular weight of 240.75 for the salt and 204.29 for the free base. Its legitimate commercial role is narrow and specific: it is a veterinary anthelmintic active pharmaceutical ingredient and, in analytical contexts, a reference standard. Because the racemate carries only half of its mass as the pharmacologically active enantiomer, its potency per kilogram differs materially from levamisole, which is why many mature markets have migrated toward the single enantiomer.

This white paper is written for licensed veterinary pharmaceutical manufacturers, their API procurement teams and qualified distribution partners. It contains no human or animal dosing, administration or clinical guidance of any kind, and it does not address consumer or retail supply. Material of this class is offered only through controlled, documented channels to entities holding the licences required in the destination country, and every enquiry is subject to buyer qualification.

The compliance perimeter is unusually demanding for a molecule of this size. Because the tetramisole/levamisole class has a documented history of appearing as an adulterant in illicit drug supply chains, responsible suppliers operate end-use declarations, know-your-customer screening, buyer qualification and licence verification before shipment, and maintain auditable diversion-control records. Alongside that sits the ordinary API quality regime: ICH Q7 current good manufacturing practice, ICH Q3A, Q3C and Q3D controls, ICH M7 assessment of aromatic amine and other mutagenic impurities, and market-authorisation prerequisites such as EU Regulation 2019/6, FDA Center for Veterinary Medicine requirements, and a European Directorate for the Quality of Medicines certificate of suitability or a drug master file.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

The molecule is a 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole, a bicyclic system in which an imidazoline ring is fused to a thiazolidine across a bridgehead nitrogen. and the hydrochloride salt delivers the aqueous solubility and solid-state stability required for formulation.

• Enantiomer Pharmacology and the Racemate Penalty: The anthelmintic activity resides predominantly in the levorotatory enantiomer, which acts as an agonist at nematode nicotinic acetylcholine receptors and produces sustained spastic paralysis of the parasite. The racemate therefore delivers roughly half the active enantiomer per unit mass, so any comparison with levamisole must be made on delivered enantiomer rather than gross weight, and the distomer adds to the overall toxicological burden.
• Salt Form, Solid State and Stability: Conversion to the hydrochloride gives a water-soluble crystalline solid suitable for drench, injectable and premix manufacture, but it also makes control of the solid form a genuine quality attribute. Manufacturers must define and consistently produce a single polymorphic form, verify it by X-ray powder diffraction supported by thermal analysis, control water by Karl Fischer titration and demonstrate ICH Q1A stability.

2.2 Synthesis and Manufacturing Technologies

Industrial manufacture is discussed here only at the level of legitimate route class, purification strategy and containment, which is all a qualified B2B counterpart needs for a meaningful audit. Detailed operating parameters are not part of any commercial offering, and enquiries framed around them are themselves a diversion indicator.

• Imidazothiazole Ring Construction and Salt Formation: At class level, producers construct the imidazo[2,1-b]thiazole bicycle by cyclocondensation of a 2-aminothiazoline equivalent with a phenyl-bearing two-carbon electrophile, then convert the base to the hydrochloride under controlled conditions. A racemate process omits the resolution or asymmetric step that an enantiopure levamisole process requires, which is why the racemate route is shorter. Process control focuses on conversion completeness and on regioisomeric and degradation impurities.
• Purification, Containment and Analytical Control: API purification relies on controlled crystallisation, polishing where required, and solvent removal under ICH Q3C limits. Because the substance is pharmacologically active, handling is governed by an occupational exposure band derived from a health-based exposure limit or permitted daily exposure, with containment, cleaning validation and occupational hygiene matched to that band. Release testing combines related substances by HPLC, enantiomeric composition by chiral HPLC, residual solvents by headspace GC, elemental impurities by ICP-MS, water, polymorph identity and a mutagenic-impurity assessment.

2.3 Core Application Matrix

• Food-Producing Animal Anthelmintic Formulations: The dominant legitimate outlet, supplying licensed manufacturers of drenches, injectables, boluses and premixes for cattle, sheep, goats, swine and poultry, where parasite control is integrated into herd-health and resistance-management programmes.
• Companion-Animal and Other Licensed Veterinary Products: A smaller, registration-heavy segment in which authorisation and pharmacovigilance sit with the marketing authorisation holder, and the API supplier supports the dossier and maintains change control.
• Reference-Standard and Analytical Quality-Control Use: Certified reference material supplied to official laboratories, residue-monitoring programmes and quality-control departments for method calibration, recovery studies and confirmation testing, and it is supplied only to verifiable institutional and licensed industrial customers.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Underlying demand is set by livestock populations and parasite prevalence, which continue to grow in Asia, Latin America and parts of Africa. A second driver is anthelmintic resistance management, where rotation and combination programmes sustain volumes of established actives.

3.2 Capacity Distribution and Export Flows

API capacity is concentrated in China and India. Chinese producers in Zhejiang, Jiangsu and Shandong supply the bulk of traded material, increasingly under cGMP systems with drug master files; Indian producers around Hyderabad and Gujarat combine API manufacture with finished-dosage capability and mature regulatory dossiers. Finished-product manufacture and registration sit predominantly with marketing authorisation holders in Europe, North America, Brazil and Australia.

3.3 Market Bifurcation and Pricing Dynamics

The market is sharply bifurcated between registered, GMP-manufactured API supported by open or referenced dossiers, and unregistered technical-grade material traded on price. The spread reflects the cost of cGMP operation, registration maintenance, solvent recovery and effluent treatment.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Two independent compliance regimes govern this molecule, and both must be satisfied before a shipment should move. The first is the veterinary medicinal product regime, which determines whether the finished product containing the API may be placed on the market at all. The second is the controlled-channel regime, which exists because this chemical class has a documented history of diversion into illicit supply chains; here the operative controls are end-use declarations, know-your-customer screening, buyer qualification and destination-country licence verification. Neither regime is optional, and neither is satisfied by a generic certificate of analysis.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• Veterinary Regulation 2019/6, MRLs and Withdrawal Periods: Finished veterinary medicines require marketing authorisation, and the active substance must be manufactured under good manufacturing practice with a supporting dossier referenced by the authorisation holder. For food-producing species, maximum residue limits and withdrawal periods govern lawful use, so exporters must support residue-depletion data and state clearly that they supply API only to licensed manufacturers. Imported active substances also carry GMP equivalence and, where applicable, written-confirmation requirements.
• REACH, CLP and Environmental Risk Assessment: The substance must hold a valid REACH registration for imports at or above one tonne per year, with classification, labelling and packaging under CLP and a target-language safety data sheet. Commonly notified classifications in this class include Acute Oral Toxicity Category 3 (H301), with further hazard categories appearing in individual dossiers, so the actual classification must always be read from the current supplier SDS. Veterinary medicinal products also undergo environmental risk assessment under the VICH guidelines, and effluent containing active residues is regulated under discharge consents.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• FDA Center for Veterinary Medicine, DMFs and cGMP: A finished veterinary drug requires an approved new animal drug application or abbreviated application, with the API supported by a referenced drug master file and manufacturing meeting ICH Q7. In practice the API specification, impurity limits, polymorph statement and stability package must be frozen under change control, because a silent process change can invalidate the applicant's filing.
• TSCA, EPA and Diversion-Focused Trade Controls: The substance must be confirmed on the TSCA inventory for import, with the standard import certification, and manufacturing or import sites remain subject to EPA environmental and effluent obligations. Beyond chemical inventory law, US-facing trade in this class is shaped by diversion-control expectations: know your customer, hold end-use declarations, verify consignee licensing and report suspicious orders.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Pharmaceutical API manufacturing faces rising scrutiny on three fronts: solvent and energy intensity, pharmacologically active residues in effluent, and upstream supply-chain transparency. For a veterinary antiparasitic these are not abstract concerns, because environmental exposure is assessed during product authorisation.

5.1 Carbon Footprint and Circular Economy

The dominant contributors are solvent use and recovery, reaction and drying energy, and the treatment of aqueous waste. Credible improvement is measured with green-chemistry metrics: process mass intensity, E-factor, solvent recovery rate and renewable electricity share. Plants supplying European customers should expect to report a cradle-to-gate footprint covering Scope 1, 2 and relevant Scope 3 inputs.

5.2 Sustainable Sourcing and Traceability

Traceability here means two things. Commercially it means full visibility of registered starting-material suppliers with qualification, change control and audit rights, because an uncontrolled upstream change is a registration risk. Environmentally it means control of active residues: validated cleaning, destruction of API-containing waste, effluent monitoring and documentation supporting the VICH Phase I and Phase II environmental risk assessment. ISO 14001 and ISO 45001 certification are now standard expectations.

VI. Supply Chain Resilience and Export Logistics

Logistics for this API balance two objectives: pharmaceutical quality and chain of custody. The material is chemically robust at controlled ambient conditions, so cold chain is generally unnecessary, but it is a pharmacologically active, potentially toxic substance, so containment, tamper evidence and traceability are mandatory rather than optional.

6.1 Packaging Standards and Moisture/Contamination Control

• Pharmaceutical Primary Packaging and Environmental Control: API is presented in double polyethylene bags inside fibre or plastic drums, sealed under controlled humidity and labelled with batch, retest date, storage condition and manufacturer. Shipments move at controlled ambient temperature, typically around 15–25 °C, protected from moisture and heat.
• Chain-of-Custody, Tamper Evidence and Record Integrity: Every drum should carry a serialised, tamper-evident closure, and every shipment a packing list reconciled to batch records, a certificate of analysis and a signed delivery record. Retained samples, secure storage with access logging and reconciliation of shipped versus received quantities are the controls that make diversion visible.

6.2 Dangerous Goods Identification and Transit Protocols

Transport classification must follow Section 14 of the safety data sheet, and for a substance in this hazard class that commonly means a toxic-substance entry such as UN 2811, Class 6.1, with the packing group set by the measured toxicity data. Where it applies, shipments must use UN-approved packaging, carry full marking, labelling and documentation, be offered by trained personnel, and comply with ADR, RID, the IMDG Code and the IATA Dangerous Goods Regulations. Carriers should be selected on security and auditability as well as price, with no uncontrolled re-routing and no consolidation through unvetted intermediaries.

VII. Enterprise Global Expansion Strategy Guide

Growth in this category is won by demonstrating control rather than by competing on price. Three priorities define credible participants.

1. Operate a Documented Diversion-Control and Buyer-Qualification Programme: Require end-use declarations and know-your-customer files before quotation, verify consignee licensing in the destination country, screen against denied parties and audit periodically with records retained. Publish a clear policy restricting supply to licensed entities, and train commercial staff to escalate red flags.
2. Win Through Registration-Led Market Entry: Secure the dossier assets that make a customer's authorisation possible: active substance master file or certificate of suitability, drug master file where required, cGMP evidence and written confirmation where applicable. Treat the registered specification as contractually frozen under formal change control.
3. Differentiate on Analytical Depth and ICH M7 Rigour: Build the impurity story properly: related substances, enantiomeric composition, residual solvents, elemental impurities and polymorph attributes controlled, and a documented ICH M7 assessment covering aromatic amine and other potentially mutagenic impurities with in silico and, where required, experimental support. Add nitrosamine risk assessment, cleaning validation and ICH Q1A stability data.

VIII. Conclusion

Tetramisole hydrochloride remains a commercially relevant veterinary anthelmintic API, but its market is defined less by chemistry than by control. Technically it is a well-characterised imidazothiazole whose racemic nature imposes a real potency and impurity-management penalty relative to levamisole; commercially it is a registered, GMP-manufactured active substance traded between licensed parties; regulatorily it sits inside both the veterinary medicinal product regime and the controlled-channel regime. Suppliers who internalise all three dimensions—and who decline business that cannot be qualified—build durable positions in a market where access is the scarce asset.

For procurement and compliance teams the test should be applied before every order: does the consignee hold the licence required in the destination country, is there a signed end-use declaration and a complete know-your-customer file, is the API covered by a current dossier reference and cGMP evidence, and does the impurity and stability package meet ICH expectations? Where the answer to any of these is no, the transaction should not proceed. This paper provides no human-use, dosing or administration guidance, and none should be requested or given.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global Tetramisole Hydrochloride Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global Tetramisole Hydrochloride supply chain:

• China — cGMP Veterinary API Manufacturing Base: Zhejiang, Jiangsu and Shandong host the largest concentration of capacity, with a widening group of plants operating to ICH Q7 expectations and holding drug master files and certificates of suitability. The leading exporters maintain buyer-qualification and diversion-control procedures consistent with customer audit expectations. Documentation quality varies considerably, so on-site audit and multi-lot evaluation remain essential.
• India — API Plus Finished-Dosage Integration: Hyderabad, Ahmedabad and Gujarat combine active-substance manufacture with finished veterinary dosage-form capability, supported by mature English-language regulatory dossiers and experience of US, EU and Latin American submissions. Their strength is registration support and change-control discipline; their exposure is dependence on imported intermediates.
• Europe and North America — Authorisation Holders, Standards and Analytical Users: This region contributes relatively little API capacity but controls the demand side: marketing authorisation holders, finished-product manufacturers, official residue-monitoring laboratories and reference-standard distributors. Participants here set the documentary bar—cGMP equivalence, written confirmation, dossier references and end-use screening—and their qualification process determines whether an overseas producer gains durable market access.